GDF15 calmed mouse livers without weight loss, via a brain-to-glucocorticoid detour

Researchers at McMaster University report in Cell Metabolism that GDF15, the hormone best known for suppressing appetite and supporting weight loss, reduced liver inflammation and slowed the development of liver scarring in mice even when weight loss did not occur ^[1]. The route they describe is indirect: GDF15 starts signalling in the brain, travels through the nervous system, and ends in the release of glucocorticoids, which then suppress inflammation in the liver ^[2].

The consequence for drug development is the decoupling. If liver benefit can be produced without a change in food intake, body weight or liver fat, then the liver endpoint and the weight endpoint are measuring different biology rather than one downstream of the other. The team says it observed the protective effects regardless of all three of those variables ^[4]. That fits an awkward clinical observation the authors point to: on the newer weight loss medications, liver inflammation can persist even after substantial weight loss ^[8]. MASH, the advanced form of fatty liver disease at issue, affects millions of people and can progress to cirrhosis, liver cancer and liver failure ^[7].

The work is in mouse models built to reproduce human MASH, interrogated with genetic, pharmacological, genomic and spatial transcriptomics methods ^[3]. No human data is described in the university's account of the study ^[14]. That distinction is worth holding onto, because the effector here is a class of steroid hormone with wide reach: the researchers describe glucocorticoids as important for metabolism, immune activity and the body's stress response ^[13]. Whether the glucocorticoid signal in this pathway is narrow enough to be therapeutically useful is not addressed in the summary ^[15].

Gregory Steinberg, professor in McMaster's Department of Medicine, co-director of its Centre for Metabolism, Obesity and Diabetes Research and senior author, says the findings show GDF15 "does much more than regulate appetite and body weight" and suggest the hormone "may be part of the body's own defense system against chronic liver injury" ^[5], ^[10]. Dongdong Wang, first and corresponding author and an assistant professor in the same department, describes the effect on immune cells as a shift "into a more protective and less active state" rather than a reduction in their number ^[6], ^[11].

This is the second distinct job the same group has assigned to GDF15. Work Steinberg and Wang published in 2023 found that the hormone helps the body maintain calorie burning during weight loss ^[9]. The new paper argues the same molecule also runs an anti-inflammatory circuit that has nothing to do with that.

One disclosure belongs in the reading: Steinberg is chief scientific officer, shareholder and co-founder of Espervita Therapeutics, and an executive member of NexusHealth at McMaster ^[12].

What to watch. First, whether the brain-to-liver arc survives translation, since neural circuits mapped in mice have a poor record of transferring intact. Second, whether anyone designs a trial that can detect the decoupling at all: the authors frame future therapies as targeting liver inflammation alongside existing treatments focused on weight and liver fat ^[8], which implies combination designs where the inflammation signal is hard to separate from the weight signal. Third, the dose ceiling. A mechanism that works by releasing glucocorticoids inherits their liabilities, and the summary does not report tolerability ^[15].